DirectoryMix Web Resources » Article Details

MOSAID Announces Share Buyback Program - Read More

Date Added: May 31, 2008 05:20:03 PM
OTTAWA, ONTARIO-- - MOSAID Technologies Inc. today announced that it has amended the terms of its normal course issuer bid through the facilities of the Toronto Stock Exchange, commenced September 13, 2007, to increase the number of common shares to be purchased from 559,583 to 1,118,731.

Category: Reference » Patents


No comments are posted yet


 
Name:*
Email:*
Website:  (optional)
Comment:*
(html and bb codes are filtered and not allowed)

Do the math:*CAPTCHA - Do The Math
 

Related Articles

Pluristem Therapeutics Announces $1.6 Million Securities Offering

Pluristem Therapeutics Inc. (Nasdaq:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of non-personalized (allogeneic) cell therapy products for a variety of degenerative, ischemic and autoimmune indications, today announced i

Penwest Begins Phase I Clinical Trial of PW 4153, Candidate For Treatment of Symptoms of Parkinson's Disease

DANBURY, Conn., July 10, 2008 -- Penwest Pharmaceuticals Co. today announced that it has begun dosing in a Phase I clinical trial of PW 4153, a drug candidate for the treatment of the symptoms of Parkinson's disease.

Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International

Onyx Pharmaceuticals, Inc. today announced that it has in-licensed a novel targeted oncology compound, BGC 945, from BTG International Limited based in the United Kingdom.

Broadcom Joins WirelessHD

BERLIN , Aug. 28 /PRNewswire-FirstCall/ -- IFA 2008-- Broadcom Corporation (Nasdaq: BRCM), a global leader in semiconductors for wired and wireless communications, today announced at the IFA Show in Berlin that it has joined the WirelessHD(TM) consortium

Avesthagen begins work on new R&D facility

Avesthagen Limited, the Bangalore-based bio-technology firm, on Wednesday said it would release its first batch of biosimilars into the market by mid-2009.